NEW YORK, Jan. 05, 2017 -- The following statement is being issued by Levi & Korsinsky, LLP:
To: All persons or entities who purchased or otherwise acquired securities of (1) PlasmaTech Biopharmaceuticals, Inc. between March 31, 2015 and June 19, 2015; and/or (2) Abeona Therapeutics Inc. (NASDAQ:ABEO) between June 22, 2015 and December 9, 2016.
You are hereby notified that a securities class action lawsuit has been commenced in the USDC for the Southern District of New York. To get more information go to:
http://www.zlk.com/pslra/abeona-therapeutics-inc
or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.
The complaint alleges that throughout the Class Period Defendants made false and/or misleading statements and/or failed to disclose that: (1) the science behind Abeona’s proposed gene therapy treatment for Sanfilippo syndrome is unviable; (2) Steven H. Rouhandeh, Abeona’s Executive Chairman and Principal Executive Officer, previously worked for a biotech promoter who was convicted of securities fraud and involved in manipulating biotech stocks; and (3) as a result, Defendants’ statements about Abeona’s business, operations and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.
On December 12, 2016, analyst firm Mako Research published a report asserting, among other things, that Abeona’s science underpinning its gene therapy approach is unviable and that Rouhandeh previously worked in a position of authority at D. Blech & Co.—a firm named after now-convicted felon David Blech.
If you suffered a loss in Abeona you have until February 14, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky is a national firm with offices in New York, New Jersey, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Levi & Korsinsky, LLP Joseph E. Levi, Esq. 30 Broad Street - 24th Floor New York, NY 10004 Tel: (212) 363-7500 Toll Free: (877) 363-5972 Fax: (212) 363-7171 www.zlk.com


CTOC Adds 3,000 Doctors, 500 Hospitals Ahead of Liquidity Push
BlackRock CEO Larry Fink Earns $37.7 Million in 2025 Amid Record Growth
SoftwareONE Posts 22.5% Revenue Surge in 2025 on Crayon Acquisition
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman
Ukrainian Drones and the #MadeByHousewives Movement: Kyiv Fires Back at Rheinmetall CEO
Star Entertainment Secures $390M Refinancing Deal to Stabilize Operations
TSMC Japan's Second Fab to Produce 3nm Chips by 2028
McDonald's and Restaurant Brands International Face Headwinds Amid Iran Conflict and Rising Costs
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal
Luxury Car Sales in the Middle East Take a Hit Amid Iran War
Chinese Universities with PLA Ties Found Purchasing Restricted U.S. AI Chips Through Super Micro Servers
SpaceX Eyes Historic IPO at $1.75 Trillion Valuation
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure
Europe's Aviation Sector on Track to Meet 2025 Green Fuel Mandate
Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026
Novartis to Acquire Biotech Firm Excellergy in $2 Billion Deal
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers 



